Objective: This study was designed to compare with placebo the dose-response effect of cyclical doses of the C21 progestogen, medroxyprogesterone acetate (MPA) on blood pressure (BP) when administered to normotensive postmenopausal women receiving a fixed mid-range daily dose of conjugated equine oestrogen (CEE). Materials and methods: Twenty normotensive postmenopausal women (median age 53 years) participated in the study which used a double-blind crossover design. There were four randomised treatment phases, each of 4 weeks duration. The four blinded treatments were MPA 2.5 mg, MPA 5 mg, MPA 10 mg and matching placebo, taken for the last 14 days of each 28 day treatment cycle. CEE 0.625 mg was also administered once daily as open labelled tablets to all subjects throughout the study. Clinic BP was measured weekly with the
Introduction
Reliable data regarding the effects of 'hormone replacement therapy' (HRT) on blood pressure remain deficient. Collectively, previous studies have variably shown no change, 1-12 a decrease 1,2,13-29 or an increase 4, 9, 11, 21, [30] [31] [32] [33] [34] [35] in blood pressure with various combinations of HRT. Unfortunately, few of the previous studies have been designed to differentiate between the effects on blood pressure of the individual oestrogen ('natural', conjugated equine or semisynthetic) and progestogen (C21 or C19 derivatives administered as cyclical or continuous therapy) components of the regimen when these preparations have been administered in combination.
The one notable exception is the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. 5 This study in healthy, normotensive postmenopausal women provided the first definitive evidence using a randomised, placebo-controlled design, that a single mid-range dose of conjugated equine oestrogen administered with randomised progestogen treatments or placebo had no significant effect on blood pressure. 5 In addition to the PEPI study, limited data on the effects of progestogens on blood pressure are available from studies of progestogen-only contraceptive formulations administered to normotensive premenopausal women. From these studies there is little evidence to suggest that contraceptive doses of progestogens given alone to normotensive premenopausal women are associated with a pressor effect on blood pressure. 31, [36] [37] [38] However, results of some studies have suggested that, while progestogen administered alone does not have a demonstrable pressor effect, when administered in combination with oestrogen in combined contraceptive formulations the progestogen may have a synergistic effect, thereby enhancing the pressor effect of the oestrogen. 37 ,39
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From the currently available data a number of questions remain unanswered. Although the results of the PEPI study were reassuring, the study did not provide information regarding the different types, doses and regimens of progestogen 'replacement' therapy currently used clinically. The effect on blood pressure and other cardiovascular parameters of a particular oestrogen-progestogen combination may depend not only on the type and dose of the oestrogen administered, but also on the type and dose of the progestogen. 37 The magnitude of any progestogen-related effect may also be influenced by the relative androgenicity of the progestogen preparation used. [40] [41] [42] [43] [44] In the present study in normotensive postmenopausal women, a randomised, double-blind crossover design was used to compare with placebo the effects on blood pressure and other cardiovascular parameters of cyclical doses spanning the clinical dose range of the C21 progestogen, medroxyprogesterone acetate, in normotensive women receiving a fixed mid-range daily dose of conjugated equine oestrogen. The study tested the null hypothesis that there would be no significant effect on blood pressure from the addition of 'replacement' doses of exogenous semi-synthetic progestogen as cyclical therapy to daily oestrogen supplementation in postmenopausal normotensive women.
Materials and methods

Subjects
Subjects included in this study were recruited by public advertisements in the Consulting Clinics at Flinders Medical Centre, a general teaching hospital of Flinders University of South Australia, and by advertisement in local news media. They were to be healthy postmenopausal women aged 60 years or less as determined by medical history, physical and gynaecological examination and screening haematological and biochemical testing. Postmenopausal status was defined as either a history of at least 12 months of amenorrhoea prior to study entry in women with an intact uterus, or a history of previous hysterectomy with or without oophorectomy, combined with biochemical evidence of menopause defined as a serum follicle-stimulating hormone (FSH) concentration у20 IU/L. 45 Subjects were required to be normotensive, defined as having a mean clinic sitting blood pressure of р140 mm Hg systolic and р90 mm Hg diastolic measured using a mercury sphygmomanometer on at least two separate occasions at least 1 week apart. They were not to be currently receiving any hormone replacement therapy and any previous hormone replacement therapy was required to have been ceased at least 1 month prior to entry into the active phases of the study. Each subject was required to undergo a pelvic examination to exclude any significant pelvic abnormality. Transvaginal ultrasound examination was performed to assess endometrial thickness and to exclude the presence of endometrial hyperplasia in women with an intact uterus. Women over the age of 50 years who had not had a mammogram within the last 2 years were required to have a mammogram to exclude breast carcinoma prior to study entry.
Subjects were excluded if they had any chronic medical illness, a history of breast cancer, clinical evidence of pelvic disease, evidence of endometrial hyperplasia (defined as endometrial thickness Ͼ5 mm), 46 previous intolerance of oestrogen or progestogen in 'replacement' doses, the need for any chronic medication likely to impact on blood pressure, 24-h urinary sodium excretion Ͻ70 mmol/day or Ͼ250 mmol/day and a body mass index of Ͼ30 kg/m 2 . Subjects were also excluded if they had a disturbance of heart rhythm (atrial fibrillation, frequent (Ͼ10/min) atrial or ventricular extrasystoles) which rendered blood pressure measurement by oscillometry inaccurate.
The study was approved by the Committee on Clinical Investigation and the Drug and Therapeutics Advisory Committee at Flinders Medical Centre. Prior to entry, all subjects were informed about the study both verbally and by an information sheet and were asked to provide written consent to participation.
Study design
The study was conducted using a randomised, doubleblind placebo controlled crossover design. Each phase was of 4 weeks duration. For each subject the order of the treatments was allocated according to a 4 × 4 balanced Latin square. Each subject was allocated a sequence of the treatments denoted by a row of the Latin square with individual treatments occupying the cells of the row. Subjects were allocated randomly (by random numbers) in blocks of four to the rows of the square and thus a treatment sequence. The columns of the square represented the treatment phases in chronological order. (A balanced Latin square is one in which each treatment occurs only once in each cell in the square and in addition occurs only once after any other treatment.)
There was no washout period between phases, but only the measurements recorded in either the last 2 weeks (blood pressure and heart rate) or at the end of each phase (ambulatory blood pressure, arterial waveform and biochemical parameters) were used for comparison, giving an effective washout period of at least 2 weeks in each phase. The active phases of the study were preceded by an open 4-week runin phase in which screening examinations were conducted, exclusion criteria were assessed and patient consent obtained.
Treatments and dosage regimens
Each subject received continuous once daily treatment with conjugated equine oestrogen (CEE) 0.625 mg throughout the four 1-month randomised treatment phases of the study. In addition they were randomised according to a balanced Latin square design to a particular sequence of the four treatment phases which were medroxyprogesterone acetate 2.5 mg (MPA 2.5 mg), medroxyprogesterone acetate 5 mg (MPA 5 mg), medroxyprogesterone acetate 10 mg (MPA 10 mg) and matching placebo (P).
Each treatment was taken orally at approximately the same time each day with the medroxyprogesterone and matching placebo taken for the last 14 days of each 28-day treatment cycle, which corresponded to the final 2 weeks of each 4-week randomised phase. Each treatment cycle commenced at the beginning of each randomised phase. The oestrogen treatments were administered as openlabelled tablets. The blinded, randomised treatments (medroxyprogesterone and placebo) were encapsulated in identical-appearing opaque gelatine capsules. The placebo preparation consisted of lactose BP powder. The study medications were purchased from Ayerst Laboratories Pty Ltd (conjugated equine oestrogen, 'Premarin') and Upjohn Pty Ltd (medroxyprogesterone acetate, 'Provera').
Study medication encapsulation, randomisation and packaging in individually labelled bottles were performed by the Pharmacy Department, Royal Adelaide Hospital, Adelaide, South Australia. Quality control testing of the study drug formulations, which included identification, disintegration and uniformity of weight analysis were conducted at the Royal Adelaide Hospital. Disintegration studies comparing the disintegration rate of encapsulated and non-encapsulated tablets showed that disintegration was unaffected by encapsulation and therefore no further pharmaceutical testing was performed.
Conjugated equine oestrogen 0.625 mg was chosen for use in the study because it was the oestrogen used in the PEPI study, and because it represents the mid-range dose of the oral oestrogen most commonly administered as hormone replacement therapy. 5, 47 Medroxyprogesterone acetate was chosen because it is the most commonly prescribed C21 progestogen as orally administered HRT. 5, 47 The three doses of MPA were selected to represent the usual clinical dose range for administration of this progestogen in 'cyclical' hormone replacement regimens.
Subjects suffering an intercurrent illness requiring treatment during the study were allowed to continue in the study provided that they did not require medications which were known to influence blood pressure or to alter the metabolism of the oestrogen and/or progestogen preparations. The prescription of any medication during the study was recorded and the reason for prescription, dose and route of administration, date of onset and cessation of treatment were noted.
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Protocol
Subjects were reviewed weekly throughout the study and measurements were made prior to the next dose of study medication approximately 24 h after the previous dose. Blood pressure was measured in the clinic using a semi-automatic sphygmomanometer (Dinamap Vital Signs Monitor 8100, Critikon Inc., Johnson & Johnson, FL, USA) which operates by the oscillometric principle. 48 A cuff of appropriate size for each subject was used by ensuring that the bladder length was at least 80% and the bladder width at least 40% of the circumference of the subject's mid-upper arm. 49 On each occasion three measurements were taken in the sitting position after at least 5 min quiet rest and then again in the standing position after 2 min standing. In each position the average of the 2nd and 3rd readings were taken as the blood pressure for that position. Blood pressure measurements were made consistently on the same arm throughout the study. Heart rate was recorded using the Dinamap and the average of the 2nd and 3rd values was recorded as the heart rate in each position. Body weight was also measured in light indoor clothing without shoes. At each visit adverse events, both spontaneously reported and in response to open questioning, were recorded. Compliance was assessed by tablet counts at each visit and expressed as a percentage of number of capsules taken/number of capsules that should have been taken in the particular period.
Ambulatory blood pressure over a 26-h period was measured during the last week of each of the four randomised treatment phases using the SpaceLabs 90207 automatic blood pressure recording system (SpaceLabs Inc, Redmond, WA, USA). Readings commenced at the time of daily drug administration and continued for 26 h. A further dose of tablets was administered at the end of 24 h (next scheduled dose period) and the recording continued for a further 2 h to complete the 26-h recording period. The first 2 h of the recording period were discarded leaving hours 2-26 for analysis. 50 Readings were taken at 15-min intervals during the day and 60-min intervals overnight. Each subject was asked to keep a diary of activities during the recording period. For each subject, 'awake' ('daytime') and 'asleep' ('night time') periods were identified from the subject's diary, and average blood pressure and heart rate were calculated separately for each of these periods. Average 24-h blood pressure and heart rate were also calculated for each recording.
Peripheral pulse waveform was recorded by applanation tonometry (SphygmoCor BPAS-1, PVW Medical, Sydney, Australia) 51 from the radial artery during the last week of each phase. The time of day at which subjects took their medication and the time of the pulse wave measurements in relation to dose were maintained constant (22-26 h post dose) in all subjects throughout the studies. The radial waveforms were used in a computerised algorithm to calculate central aortic pressures and systolic augmentation, as well as aortic pulse waveforms and additional parameters of left ventricular function. 52 At the end of each phase a fasting venous blood sample was collected after 5 min of quiet rest in the supine position, for measurement of plasma renin activity (PRA), 53 and plasma concentrations of electrolytes, urea and creatinine (standard autoanalyser techniques), and aldosterone. 54 Pre-dose serum oestradiol (DiaSorin IRMA kit; DiaSorin s.r.l., Saluggia, Italy), follicle stimulating hormone (FSH) (Bioclone IRMA kit; Bioclone Australia Pty Ltd, Marrickville, New South Wales, Australia), and sex hormone binding globulin (SHBG) (Orion IRMA kit; Orion Diagnostica, Orion Corporation, Espoo, Finland) concentrations were also measured. At the end of each phase subjects were required to perform a 24-h urine collection for measurement of 24-h urinary sodium excretion. In addition at the end of each phase subjects had a physical examination to assess any changes in physical status.
Data analysis
The average values for parameters in each phase of the study were compared by repeated measures analysis of variance (BMDP Windows New System, Professional Edition, 5V, UCLA, Los Angeles, CA, USA, 1993) with treatments, position of measurements (clinic blood pressure values) and time of day (ambulatory blood pressure values) as main withinsubject factors and baseline (pre-randomisation) values as covariate. For clinic blood pressure, heart rate and body weight, the means of the values in the last 2 weeks of each phase were used in the analysis. For the other parameters, the values at the end of each phase were compared. For each ambulatory blood pressure record 'daytime', 'night time' (corresponding to 'awake' and 'asleep' periods extracted from the subject's diary) and 'average 24 h' values were calculated and then comparisons between phases were made for each of these values. The methods inherent to the BMDP 5 V statistical package with appropriate reduction of degrees of freedom were used to impute values for the missing data from subjects in whom values from only one or two phases were missing. 55 Subjects in whom values from more than two phases were missing were excluded from the analyses.
Pairwise comparisons among individual treatments for each parameter were made using model predicted mean values and their covariance to generate estimate differences standardized by the estimated error of the difference as 'z-scores'. These 'zscores' were assumed to be approximated by a standard normal distribution. To allow for the multiple comparisons the Dunn-S idák procedure [P* = 1−(1−P) k ] was used. 56 A probability of P Ͻ 0.05 (after Dunn-S idák correction where appropriate) was regarded as statistically significant.
A random-effects generalised least squares regression model was used to test for a relationship between progestogen dose and clinic, ambulatory and calculated aortic blood pressure parameters. 57 Friedman's test for repeated measures relating to non-parametric data was used for sex hormone binding globulin and oestradiol. 58 Median values for each treatment group were substituted for missing values.
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Results
Subjects
Twenty subjects entered and completed the randomised treatment phases of the study. Their median age was 53 years (range: 46-60 years). At randomisation, average clinic sitting blood pressure was 122 ± 3/65 ± 3 mm Hg (mean ± s.e.), average weight was 75 ± 3 kg and average 24-h urinary sodium excretion was 133 ± 12 mmol/day. Overall median compliance was 100% (range: 90-102%).
Clinic pre-dose blood pressure, heart rate and weight
Compared with placebo, there were no significant changes in clinic systolic, diastolic or mean arterial blood pressures in any of the phases with cyclical progestogen (Table 1 ). There was a small increase in clinic heart rate with MPA 5 mg when compared with MPA 2.5 mg (P Ͻ 0.01) and MPA 10 mg (P Ͻ 0.05) treatments, but there were no changes in clinic heart rate with any of the progestogen treatments when compared with placebo. There was a significant effect of change in position (P Ͻ 0.01) in all phases with an increase in diastolic blood pressure and heart rate between the sitting and standing positions. There was no significant change in body weight with any of the treatments.
Ambulatory blood pressure and heart rate
Average ambulatory daytime diastolic blood pressure was reduced with the progestogen treatments, with the reduction being significant in the MPA 10 mg phase (P Ͻ 0.05) ( Table 2) . A significant doseresponse relationship across the range of progestogen doses used was shown for daytime diastolic and daytime mean arterial blood pressures (P Ͻ 0.05). Average ambulatory daytime systolic blood pressure and night time systolic, diastolic and mean blood pressures were unchanged in the progestogen phases compared with placebo. No change in average 24-h, daytime or night time ambulatory heart rate was observed with the progestogen treatments.
Calculated aortic pressures and pulse waveform
No changes in calculated aortic systolic or diastolic blood pressures were observed during the randomised treatment phases (Table 3 ). There were no changes in calculated aortic systolic augmentation indices in any phase.
Renin-angiotensin system
There were no changes in plasma renin activity or plasma aldosterone concentration with any of the The values are model-predicted means (± s.e.) from the BMDP analysis. PRA (ngAl/ml/h) 2.3 ± 0.8 3.0 ± 0.8 2.0 ± 0.8 1.9 ± 0.8 PA (ng/100 ml) 11.8 ± 2.0 11.1 ± 2.0 11.5 ± 2.0 12.2 ± 2.0
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The values are model-predicted means (± s.e.) from the BMDP analysis, and were obtained assuming a mean baseline value for all subjects. The values for FSH are model-predicted means (± s.e.) from the BMDP analysis. Analysis of SHBG and E2 by Friedman's nonparametric test for multiple comparisons. *P Ͻ 0.05 vs placebo.
progestogen treatments compared with placebo (Table 4) .
Markers of oestrogen action
A reduction in serum SHBG was observed with the MPA 5 mg and MPA 10 mg treatments (P Ͻ 0.05) and for serum FSH in the MPA 10 mg phase (P Ͻ 0.05) ( Table 5 ). Serum oestradiol was unchanged between treatments.
Plasma electrolytes and 24-h urinary sodium excretion
No clinically significant changes in plasma sodium, potassium, chloride, urea or creatinine concentrations were observed with the progestogen treatments compared with placebo. There was no significant change in 24-h urinary sodium excretion in any phase.
Adverse effects
The most commonly reported adverse effects which included headache, hot flushes, mastalgia and fatigue were reported in all four treatment phases and did not appear to be dose-related.
Discussion
In this study in healthy normotensive postmenopausal women receiving a fixed mid-range dose of Journal of Human Hypertension conjugated equine oestrogen, the addition of medroxyprogesterone acetate, administered in a cyclical regimen in three different doses spanning the usual clinical dose range, produced no change in clinic blood pressure, and no change or a small dosedependent reduction in ambulatory blood pressure parameters when compared with placebo. Calculated aortic pressures, augmentation indices and pulse waveform did not differ between phases. There was no change in body weight in any phase. No change in plasma renin activity or plasma aldosterone concentration was observed with the progestogen treatments. Suppression of serum FSH concentration occurred with the highest dose of progestogen and a small reduction in serum SHBG concentration was observed in the progestogen phases compared with placebo. There was a wide variation in measured serum oestradiol concentrations across the group but there were no significant changes in serum concentration between treatment phases.
The majority of previous studies of the effects of postmenopausal hormone replacement therapy on blood pressure have failed to differentiate between the effects of the individual oestrogen and progestogen components on blood pressure when these preparations have been administered in combination. 5 Very few data are available relating to the specific effects on blood pressure of different types, doses and regimens of progestogen. The current study used a double-blind, randomised, placebocontrolled design with adequate power to detect small changes in clinic and ambulatory blood pressure produced by different doses of a C21 progestogen administered in a cyclical regimen in doses spanning the usual clinical dose range combined with a fixed daily dose of oral oestrogen. The results of the current study are consistent with those of previous studies, including the PEPI study, which have found no change [2] [3] [4] [5] [6] [7] [8] [9] [10] 12 or a reduction [24] [25] [26] 29 in blood pressure associated with the addition of a progestogen to 'replacement' doses of oestrogen.
The results of the present study are in contrast to studies which have shown a synergistic pressor effect when progestogen is added to oestrogen for administration to premenopausal women for the purpose of oral contraception. 31, [36] [37] [38] Contraceptive preparations tend to differ from 'postmenopausal replacement' regimens in that they consist of combinations of the 'potent' semisynthetic oestrogens ethinyloestradiol or mestranol, often with the relatively androgenic C19 progestogens, both administered in doses in excess of those used in HRT. 60 The relatively higher doses and potency of the preparations used in oral contraceptive formulations may therefore influence the effects on the vasculature and blood pressure.
We have previously shown that the effect of postmenopausal oestrogen replacement therapy on blood pressure is influenced by the type and dose of oestrogen administered. 1 The effect of the progestogenic component of the hormone replacement regimen may be of equal importance and complexity with the effects on vascular reactivity dependent on the combination of dose, type, route and pattern of administration of the progestogen. [40] [41] 44 Studies have shown that synthetic progestogens may exert a relative vasoconstrictor effect on the vasculature, the magnitude of the effect being proportional to the relative 'androgenicity' of the individual preparation. [40] [41] [42] 44 In contrast to the vasoconstrictor effects observed with the 'androgenic' progestogens, the 'non-androgenic' progestogens including progesterone and medroxyprogesterone (which was used in the current study) have been shown to have a net vasodilator effect. 38, 41, 44 The observations in the present study examining the dose-response of cyclical MPA in the presence of a fixed replacement dose of oestrogen are consistent with MPA having either no net effect on vascular tone or a small net vasodilator effect. The mechanisms of the effect of the different progestogens on the vasculature remain unclear and warrant further investigation.
In addition to the proposed direct adverse effects of 'androgenic' progestogens on vascular reactivity, it has been suggested that these preparations may also exert an additional unfavorable influence on blood pressure through a tendency to induce sodium and water retention, with associated oedema and weight gain. 40, 43 In the present study no change in body weight, 24-h urinary sodium excretion or activity of the circulating renin-angiotensin system was observed with any of the 'non-androgenic' MPA treatments.
Systolic augmentation of the aortic arterial pulse is observed with normal aging and contributes to the disproportionate increase in systolic blood pressure observed with increasing age. 61 It may also contribute to adverse effects on cardiovascular function. 62 Changes in aortic systolic and diastolic pressures and in aortic systolic augmentation may occur without measurable change in peripheral arterial blood pressure. 61, 62 In the present study no significant change was noted to occur in any of the calculated aortic pressure indices including augmentation index with the different doses of cyclical MPA.
Although the present study used a fixed dose of oestrogen combined with variable doses of progestogen, a small but dose-dependent reduction in FSH was noted to occur with the progestogen treatments. This is consistent with previous studies which have demonstrated suppression of FSH concentration following administration of progestogen, independent of oestrogen. 40, 63 The suppressive effect is believed to be due to a direct effect on the gonadotropinproducing cells of the anterior pituitary. 40 A small reduction in SHBG concentration was also demonstrated with the progestogen treatments compared with placebo. The reduction in serum FSH and SHBG 64 shown in the present study confirm that the biological effects of medroxyprogesterone acetate were demonstrable despite the relative lack of effect on blood pressure. Although there was wide interindividual variation in plasma concentrations of measured oestradiol, there was no significant difference in concentrations between treatment phases to contribute to the change in SHBG concentration. The wide variability in measured circulating serum oestradiol concentrations is likely to reflect the complex composition of the conjugated equine oestrogens used in the study, together with variable back conversion of oestrone to oestradiol. 65 In conclusion, this study has shown that in a regimen of postmenopausal hormone replacement therapy with a fixed daily dose of oestrogen combined with a cyclical regimen of a C21 progestogen spanning the current clinical dose range, the progestogen has either no effect or produces a small dose-dependent reduction in blood pressure over one cycle of treatment. The effects of different progestogen preparations on the vasculature are complex and more information is required regarding the effects of the different types, doses, regimens and methods of administration of progestogens currently used in postmenopausal hormone replacement therapy to determine whether there are differences between the preparations in effect on blood pressure and related parameters or whether the effects are consistent across the different preparations.
